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Objectives : The purpose of this study was to determine
the population-attributable risk (PAR) and estimate the total
medical  expendi ture of  the Korean Nat ional  Heal th
Insurance (KNHI) due to smoking. 
Methods : We used data f rom the Korean Cancer
Prevention Study of 1,178,138 Koreans aged 30 to 95.
These data were available from 1992 to 2003 and covered
a long-term follow-up period among the Korean population.
Results : The total medical expenditure of KNHI related
to smoking increased by 27% from $324.9 million in 1999 to
$413.7 million in 2003. By specific diseases, smoking-
attributable KNHI medical expenditure was the highest for
lung cancer ($74.2 million), followed by stroke ($65.3
million), COPD ($50.1 million), CHD ($49 million) and
stomach cancer ($30 million). A total of 1.3 million KNHI
patients were suffering from smoking-related diseases in
2003. We predicted rises in total KNHI medical expenditure
related to smoking to $675.1 mi l l ion (63% increase
compared with that of 2003) and in the total number of
KNHI patients suffering from smoking-related diseases to
about 2.6million (an approximate 100% increase compared
with those in 2003) in 2015.
Conclusions : We found a substantial economic burden
related to the high smoking prevalence in South Korea.
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Annual tobacco consumption has been
steadily increasing since 1945 when the
Korean Tobacco and Ginseng Public
Corporation began the production and
purchase of tobacco leaves along with the
manufacture and sale of tobacco products. A
statistical report from the Institute of Economic
Planning reported 265,000 deaths in Korea for
the entire year of 1979, including 522 due to
lung cancer (369 men and 153 women). These
deaths due to lung cancer accounted for only
0.2% of the total deaths for 1979. 
However, in 2003, after 24 years, the number
of deaths due to lung cancer had increased
24.4-fold (n=12,725; 9,345 men and 3,380
women), to 5.2% of the total deaths, according
to the National Statistical Office. The major
explanation for this sudden increase of deaths
due to lung cancer is the higher prevalence of
tobacco consumption. 
Numerous studies found that smoking is the
main etiology of several malignant tumors,
respiratory diseases and cardiovascular
diseases [1-6]. After recognizing the serious
health consequences and national burden of
smoking, many countries sought to reduce its
prevalence rate using several measures such as
tobacco price raise and public campaigns. In
order to maximize the outcome of these
government efforts against tobacco
consumption, we need to investigate the
empirical evidence for anti-smoking policy,
including smoking-attributable diseases and
their economic burden. Although a few studies
have investigated the diseases and national
burden due to smoking in Korea [7-10], they
could not use the Korean longitudinal data
more than 10 years in estimating the
population-attributable risk (PAR) of smoking
that is needed to calculate the national burden
attributed to smoking. Therefore, the present
study attempts to predict how smoking is
influencing the total annual medical
expenditure in the Korean National Health
Insurance (KNHI) by using 11 years of
longitudinal data and KNHI benefit statistics.
The purpose of this study was to determine
the smoking PAR and estimate the total annual
KNHI medical expenditure due to smoking.
The total annual KNHI medical expenditure
means the total annual money paid by both the
KNHI as benefits and patients as co-payments
in order to purchase the medical services
included in the KNHIRs statutory benefit
services catalogue. KNHI has population
coverage of about 97%, with the remaining 3%
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METHODS
S. Study Data and Smoking-Related
Diseases
We used the data from the Korean Cancer
Prevention Study (KCPS) of 1,329,525
Koreans aged 30 to 95 years who participated
in biennial health examinations of NHI
Corporation (NHIC) to estimate the relative
risk and smoking PAR in given diseases caused
by smoking. These data have been available
from 1992 until the present and they included
long-term follow-up among the Korean
population. We used the data of health
examinations, which were collected during the
period from 1992 to 1995 from civil service
workers and private school teachers and their
dependants. We then followed these
participants for 11 years, from 1992 to 2003, to
study the effects of smoking on different
smoking-related diseases. After excluding
missing variables, the final study sample
comprised 1,178,138 individuals (804,937 men
and 373,201 women). The most important
diseases caused by smoking are shown in
Table 1.
T. Method for Estimation of Smoking-
Attributable KNHI Medical Expen-
diture
The total medical expenditure and total
number of patients with smoking-related
diseases in KNHI were calculated by
multiplying both the total annual medical
expenditure per patient of smoking-related
diseases and the number of patients by PAR.
Detailed methods on the calculation of PARs
for different diseases were reported in our
previous research [11-13]. 
The main outcome variable was the
incidence of smoking-related diseases. For
those individuals with more than one event
during the follow-up period from January 1993
to December 2003, we included only the first
event in our statistical analyses. Nonfatal and
fatal outcomes were ascertained from data on
the NHIC claim and death certificate,
respectively. We examined KNHI medical
costs incurred among smokers to treat four
major disease categories (cancer, cardiov-
ascular, respiratory, and gastrointestinal
disease; see tables 2, 3 and 4) proven to be
caused by smoking [13,14].    
Since our assumption of the occurrence of
smoking-related outcomes was made based on
people aged over 30 years old, we excluded the
data of participants aged less than 30 years
from our analysis. The following formulas
were used in the calculations:
Number of patients suffering from smoking-
related diseases = U (total patients (inpatient
+ outpatients) for a given disease among
people over 30 years of age x PAR of Smoking)
--------------------------------------------- Formula 1
Number of hospitalization suffering from
smoking-related diseases = U (total
hospitalization for a given disease among
people over 30 years of age x PAR of Smoking)
-------------------------------------------- Formula 2
Smoking-attributable KNHI Medical
Expenditure = U(KNHI Medical Expenditure
for a given disease among people over 30
years of age x PAR of Smoking)--
---------------------------------------------Formula 3
In these formulas, PAR = Smoking Rate x
(Relative Risk - 1) / [Smoking Rate x (Relative
Risk - 1) + 1], based on the reported smoking
rate in 1990. 
The predicted number of patients and the
KNHI medical expenditure attributed to
smoking until 2015 were calculated using a
regression analysis based on available data
from 1999 through 2003. The following
formula was used:
Predicted KHNI Medical Expenditure
=Intercept (a) x Regression Coefficient (b) x
Estimated Year ------------------------ Formula 4
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Table 1. Pattern of the total medical expenditure of Korean National Health Insurance (KNHI)

















































































































































































































Treatment cost for patients 
over 30 years of age
Total treatment cost 
20032002200120001999
Smoking-attributable KNHI medical expenditure
PAR[RRs*Diseases
*Relative Risks, [Population-Attributable Risk (PAR); adjusted for age, sex, alcohol drinking, exercise, and body mass index
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from smoking-related diseases increased 1.4-
fold from 961,814 in 1999 to 1,347,161 in
2003. However, the total number of KNHI
patients suffering from any disease increased
by only 14.5% from 35,515,327 in 1999 to
40,667,936 in 2003. Among the KNHI patients
suffering from smoking-related diseases, the
most common disease in 2003 was COPD
(728,909), followed by diabetes (144,606) and
CHD (134,423). The proportion of KNHI
patients suffering from smoking-related
diseases was 6.1% of the total number of
KNHI patients over 30 years of age in 2003.
.^ Changes in the Number of Hospital-
izations of KNHI due to Smoking-
Related Diseases
Table 4 shows the trend in the number of
hospitalized patients of KNHI due to smoking-
related diseases by disease and year. The total
number of hospitalized patients of KNHI due
to smoking-related diseases increased by
$185.8 million in 1999, $199.2 million in
2000, $236.0 million in 2001, $246.6 million
in 2002 and $273.4 million in 2003. The total
KNHI hospitalization cost attributed to
smoking in 2003 increased by 47.1%
compared to the cost in 1999. The total KNHI
hospitalization cost attributed to smoking for
lung cancer was the highest ($57.7 million),
followed by stroke ($57.1 million). The total
KNHI cost of hospitalization for all diseases
increased by 41.5% from $3.7 billion in 1999
to $5.3 billion in 2003. The proportion of the
total KNHI hospitalization costs attributed to
smoking was 6.4% in 2003. 
_. Changes in the Number of the
KNHI Patients Suffering from
Smoking-Related Diseases
Trends in the number of the KNHI patients
suffering from smoking-related diseases are
shown by specific disease and year in Table 3.
The number of the KNHI patients suffering
The monetary data are presented in US
dollars at an exchange rate of 1 US dollar to
1,000 Korean won. All results are presented
with combined genders.
RESULTS
S. Smoking-Related Diseases and
Population-Attributable Risk (PAR)
There were a total of 24 smoking-related
diseases (Table 1). The PAR was the highest
for laryngeal cancer (70.22%), followed by
55.07% for lung cancer, 54.97% for
esophageal cancer and 33.53% for bladder
cancer. Both smoking-attributable and relative
risks were used in conjunction to estimate the
medical expenditure and the number of
patients with smoking-related diseases. 
T. Pattern of the Total Medical Ex-
penditure of KNHI Attributed to
Smoking
The total KNHI medical expenditure
attributed to smoking increased by 27.3% from
$324.9 million in 1999 to $413.7 million in
2003, while the total expenditure for all
diseases increased by 28.4% from $10.7 billion
to $13.8 billion (Table 1). By specific diseases,
smoking-attributable KNHI medical
expenditure for lung cancer was the highest
($74.2 million), followed by stroke ($65.3
million), chronic obstructive pulmonary
diseases (COPD) ($50.1 million), coronary
heart diseases (CHD) ($49 million) and
stomach cancer ($30 million). The proportion
of smoking-attributable total KNHI medical
expenditure was about 4.1% of the total KNHI
medical expenditure spent by people over 30
years of age in 2003.
.` Pattern of the Total KNHI Hospital-
ization Costs Attributed to Smoking
Table 2 shows the pattern of the total KNHI
hospitalization costs attributed to smoking by
disease and year. Overall, the total KNHI
hospitalization cost attributed to smoking was
Table 2.  Pattern of the total hospitalization costs of Korean National Health Insurance (KNHI)


















































































































































































































Hospitalization cost for patients 
over 30 years of age
Total hospitalization cost 
20032002200120001999
Smoking-attributable KNHI medical expenditure
PAR[RRs*Diseases
*Relative Risks, [Population-Attributable Risk (PAR); adjusted for age, sex, alcohol drinking, exercise, and body mass index
23.1% from 79,176 in 1999 to 97,492 in 2003.
However, the total number of hospitalized
patients of KNHI due to any disease increased
by 16.5% from 3,115,736 in 1999 to 3,629,064
in 2003. Of the hospitalized patients of KNHI
in 2003, 16,450 were due to CHD caused by
smoking, 14,425 to COPD and 13,095 to
stroke. The proportion of hospitalized patients
of KNHI due to smoking-related diseases was
about 4.0% in 2003.
a. Predictions of the Medical Expen-
diture and the Number of Patients
with Disease Attributed to Smoking
in KNHI
We estimated the projected number of
patients suffering from smoking-related
diseases as well as the total medical
expenditure in KNHI for 2004 to 2015 through
regression analysis using the data from 1999 to
2003 (Table 5). The total KNHI medical
expenditure attributed to smoking was
estimated to increase by 63%, from $413.7
million in 2003 to $675.1 million in 2015.
Moreover, it is predicted that there will be
about 2,637,817 patients in 2015, which can be
expressed as a 96% increase.
DISCUSSION
In the present study we attempted to estimate
the total number of patients of KNHI suffering
from smoking-related diseases and the total
medical expenditure attributed to smoking in
KNHI from 1999 through 2003 among the
Korean population using an epidemiologic
approach: PAR. The estimated total KNHI
medical expenditure due to smoking was
$413.7 million in 2003. After extrapolation of
these data, we predicted that the total KNHI
medical expenditure in 2010 would be $562.0
million, rising to $675.1 million in 2015. Kang
et al. reported that the direct medical costs for
treating smoking-related diseases among
patients over 35 years of age were estimated to
be about $194.25 million in 1998 [14].
According to the results of the research by
Kang et al. the direct medical cost was 194.25
million dollars (6.57%) out of 2,956.75 million
dollars for the total smoking-related economic
cost. The direct non-medical cost was less than
1% of the total smoking-related economic cost
and the remaining economic costs (90. 6%)
were due to the loss caused by the premature
deaths.
The changes in smoking prevalence have a
direct, but delayed, effect on the medical costs.
In Korea, the smoking prevalence rose from
1980 to 2000, but has subsequently decreased
since 2000. The present study used the
smoking prevalence data from 1990 when the
smoking prevalence was high in Korea. The
study hypothesized that the loss due to
smoking in 1990 would last for over 25 years
and that the ending year for the loss due to
smoking in 1990 would be 2015. The effects of
the dramatic drop in smoking prevalence since
2000 in Korea would appear after 2020. In the
present study we estimated the total KNHI
medical cost only due to smoking-related
chronic illnesses. If the study included
smoking-related acute illnesses, the total KNHI
medical costs due to smoking would be much
more burdensome.
This study suffered several limitations, which
need to be considered. First, the total KNHI
medical expenditure in this study was
calculated by combining the cost paid by
KNHI and the statutory cost co-paid by the
patient in the utilization of KNHI-covered
medical services. Therefore, in the calculation
of the total KNHI medical expenditure, we did
not include the costs spent on medical services
not covered by KNHI. Kim et al. reported in
2004 that the cost paid by the patient for
medical services that are not covered by KNHI
accounted for about 20% of the total medical
expenditure in South Korea [15]. To calculate
the total medical expenditure including the cost
for medical services that are not covered by
KNHI, the total KNHI medical expenditure
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Table 3.  Change in the number of patients of Korean National Health Insurance suffering from


















































































































































































































Number of patients over 30 
years of age
Total number of patients in all 
age groups 
20032002200120001999
Number of patients suffering from smoking-related diseases
PAR[RRs*Diseases
*   Relative Risks, [Population-Attributable Risk (PAR); adjusted for age, sex, alcohol drinking, exercise, and body mass index
bU (total patients (inpatient + outpatients) for a given disease among people over 30 years of age x PAR of Smoking) 
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must be multiplied by 1.25. Furthermore, to
detail completely the total annual medical
expenditure in Korea, the medical expenditure
spent by beneficiaries of the Medicaid
program, containing about 3% of the Korean
population, needs to be considered.
Second, the size and validity of the relative
risk (RR) and PAR to estimate the total medical
expenditure were limited. Other studies from
the US and UK were more powerful in terms
of the study period (more than 50-year follow-
up), and they also produced more reliable
(higher) RR and PAR results [5,16,17].
However, our study results were generated
from an 11 year-cohort study, which may have
been a factor in the difference in results. The
lower rate of RR and PAR in the study can be
explained by the short follow-up. Studies
reported by Doll et al. showed that a longer
follow-up period produces a higher RR and
PAR. The RR for lung cancer was 8.0 after 20
years of follow-up, and increased approx-
imately two-fold (RR=14.9) in the 40-year
follow-up. However, the size of data in the
present study was 200-fold bigger than those of
the US or UK studies that enrolled only about
5,000 participants. Even though the follow-up
period of this study was only 11 years, the large
sample of the present study increased the
statistical power to calculate the risk for
different outcomes. 
Nevertheless, the present study is important
due to the high burden of smoking-related
diseases, high prevalence (about 50%) of
smoking among Korean men, and
skyrocketing prevalence among Korean
women. According to the latest study with
similar methodology, Kim et al. reported a
direct medical cost related to smoking in 2001
of $233.1 million, which increased 1.77-fold to
$413.7 million in 2003 [10]. Meng [18]
reported 24,388 deaths related to smoking in
1985, among adults aged over 30 years in
Korea. The most recent studies have reported
that there were 46,208 deaths related to
smoking in 2003 [13]. 
In general, the relative risks of smoking on
diseases in Asian countries, including South
Korea, are lower than those observed in
western countries during the same time
intervals [12]. Therefore, the total medical
expenditure of KNHI due to smoking might be
underestimated, possibly due to differences in
historical smoking patterns between Korea and
western countries. Smoking prevalence
increased after World War I in the US and UK,
but only after World War II in Asian countries,
resulting in a 40-year lag in health
consequences. Thirty years ago the average age
at which a person started smoking was 25
years, but this has been reduced to be 15 years
nowadays [19]. According to a survey on
tuberculosis prevalence, the average daily
cigarette consumption in South Korea
increased from 12 cigarettes in 1980 to 17 in
1985 [20]. The same trend has occurred in
China where the average daily cigarette
consumption increased from one cigarette in
1952 to 16 in 1996 [21]. 
We used our own Korean data to estimate the
total and disease-specific RR and PAR for
treatment prevalence and mortality from
smoking-related diseases. Continuing to study
this long-term cohort will yield more accurate



















































































































































































































Number of hospitalization over
30  years of age
Total number of hospitalization
in all age groups 
20032002200120001999
Number of hospitalizations suffering from smoking-related diseases
PAR[RRs*Diseases
*Relative Risks, [Population-Attributable Risk (PAR); adjusted for age, sex, alcohol drinking, exercise, and body mass index
bU (total hospitalization for a given disease among people over 30 years of age x PAR of Smoking) 
Table 5. Predictions of the total medical expen-
diture and the number of patients with
diseases attributed to smoking in
Korean National Health Insurance















































data regarding the risks of smoking by specific
diseases, and these data will be useful base
sources for other studies. In this regard, our
study provides evidence of the strong need to
develop a national policy for the effective
reduction of tobacco consumption in South
Korea. 
SUMMARY & CONCLUSIONS
Our study provided empirical evidence of
potential savings that Korea could achieve by
implementing effective tobacco control
policies by quantifying the total medical
expenditure from NHI attributable to smoking. 
In conclusion, we found that in addition to a
high smoking prevalence, there is a substantial
economic burden related to smoking in South
Korea. If we do not initiate a nationwide action
for controlling tobacco consumption, the total
medical expenditure will continue to increase
in the future.
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